Cytokinetics (CYTK)
NASDAQ:CYTK
Holding CYTK?
Track your performance easily

Cytokinetics (CYTK) Ownership - Who Owns Cytokinetics?

998 Followers

Cytokinetics (CYTK) Ownership Overview

0.72%35.91%1.82%23.54%38.00%
1.82% Other Institutional Investors
23.54% ETFs
38.00% Public Companies and
Individual Investors
The ownership structure of Cytokinetics (CYTK) stock is a mix of institutional, retail, and individual investors. Approximately 61.28% of the company’s stock is owned by Institutional Investors, 0.72% is owned by Insiders, and 38.00% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 04, 2024
Robert Blum
President & Ceo,director
xxxxxxxxxxxxx
$258150
Oct 31, 2024
xxxxxxxxxxxxx
$232617
Oct 31, 2024
Fady Ibraham Malik
Evp Research & Development
xxxxxxxxxxxxx
$378930
Oct 16, 2024
Fady Ibraham Malik
Evp Research & Development
xxxxxxxxxxxxx
$395554

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
11,333,901Institution9.63%657,139,580
10,067,248Institution8.56%583,699,039
9,870,507Institution8.39%572,291,996
4,287,095Institution3.64%248,565,768
4,067,922Institution3.46%235,858,118
2,252,713Institution1.91%130,612,300
1,821,115Institution1.55%105,588,248
1,598,152Institution1.36%92,660,853
1,596,371Institution1.36%92,557,591
1,497,941Institution1.27%86,850,619

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
9,870,507Institution8.39%572,291,996
4,067,922Institution3.46%235,858,118
2,252,713Institution1.91%130,612,300
1,821,115Institution1.55%105,588,248
1,598,152Institution1.36%92,660,853
1,596,371Institution1.36%92,557,591
1,497,941Institution1.27%86,850,619
1,458,239Institution1.24%84,548,697
1,246,559Institution1.06%72,275,491
1,232,709Institution1.05%71,472,468

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,716,402Institution3.16%207,523,888
3,749,268Institution3.19%197,961,350
3,111,194Institution2.64%180,387,028
2,945,234Institution2.50%155,508,355
2,414,357Institution2.05%134,817,695
1,765,697Institution1.50%93,228,802
1,624,169Institution1.38%85,756,123
997,654Institution0.85%57,843,979
942,691Institution0.80%54,657,224
800,375Institution0.68%46,405,743

FAQ

Who Owns Cytokinetics (CYTK)?
According to the latest TipRanks data, approximately 1.82% of the company's stock is held by institutional investors, 0.72% is held by insiders, and 38.00% is held by retail investors.
    What percentage of Cytokinetics (CYTK) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 1.82% of Cytokinetics (CYTK) stock is held by institutional investors.
      What percentage of Cytokinetics (CYTK) stock is held by retail investors?
      According to the latest TipRanks data, approximately 38.00% of Cytokinetics (CYTK) stock is held by retail investors.
        Who owns the most shares of Cytokinetics (CYTK)?
        Vanguard owns the most shares of Cytokinetics (CYTK).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis